Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution - PubMed (original) (raw)
Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution
M D Planas-Silva et al. Mol Cell Biol. 1997 Jul.
Abstract
In order to elucidate the mechanisms by which estrogens and antiestrogens modulate the growth of breast cancer cells, we have characterized the changes induced by estradiol that occur during the G1 phase of the cell cycle of MCF-7 human mammary carcinoma cells. Addition of estradiol relieves the cell cycle block created by tamoxifen treatment, leading to marked activation of cyclin E-cdk2 complexes and phosphorylation of the retinoblastoma protein within 6 h. Cyclin D1 levels increase significantly while the levels of cyclin E, cdk2, and the p21 and p27 cdk inhibitors are relatively constant. However, the p21 cdk inhibitor shifts from its association with cyclin E-cdk2 to cyclin D1-cdk4, providing an explanation for the observed activation of the cyclin E-cdk2 complexes. These results support the notion that cyclin D1 has an important role in steroid-dependent cell proliferation and that estrogen, by regulating the activities of G1 cyclin-dependent kinases, can control the proliferation of breast cancer cells.
Similar articles
- Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.
Foster JS, Henley DC, Bukovsky A, Seth P, Wimalasena J. Foster JS, et al. Mol Cell Biol. 2001 Feb;21(3):794-810. doi: 10.1128/MCB.21.3.794-810.2001. Mol Cell Biol. 2001. PMID: 11154267 Free PMC article. - Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells.
Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL. Doisneau-Sixou SF, et al. Endocr Relat Cancer. 2003 Jun;10(2):179-86. doi: 10.1677/erc.0.0100179. Endocr Relat Cancer. 2003. PMID: 12790780 Review. - Perspectives for cancer therapies with cdk2 inhibitors.
Wadler S. Wadler S. Drug Resist Updat. 2001 Dec;4(6):347-67. doi: 10.1054/drup.2001.0224. Drug Resist Updat. 2001. PMID: 12030783 Review.
Cited by
- New insights on the role of hormonal therapy in ovarian cancer.
Simpkins F, Garcia-Soto A, Slingerland J. Simpkins F, et al. Steroids. 2013 Jun;78(6):530-7. doi: 10.1016/j.steroids.2013.01.008. Epub 2013 Feb 8. Steroids. 2013. PMID: 23402742 Free PMC article. Review. - The p53-estrogen receptor loop in cancer.
Berger C, Qian Y, Chen X. Berger C, et al. Curr Mol Med. 2013 Sep;13(8):1229-40. doi: 10.2174/15665240113139990065. Curr Mol Med. 2013. PMID: 23865427 Free PMC article. Review. - Crosstalk between the insulin-like growth factors and estrogens in breast cancer.
Yee D, Lee AV. Yee D, et al. J Mammary Gland Biol Neoplasia. 2000 Jan;5(1):107-15. doi: 10.1023/a:1009575518338. J Mammary Gland Biol Neoplasia. 2000. PMID: 10791773 Review. - MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers.
Mohseni M, Cidado J, Croessmann S, Cravero K, Cimino-Mathews A, Wong HY, Scharpf R, Zabransky DJ, Abukhdeir AM, Garay JP, Wang GM, Beaver JA, Cochran RL, Blair BG, Rosen DM, Erlanger B, Argani P, Hurley PJ, Lauring J, Park BH. Mohseni M, et al. Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17606-11. doi: 10.1073/pnas.1408650111. Epub 2014 Nov 24. Proc Natl Acad Sci U S A. 2014. PMID: 25422431 Free PMC article. - The cyclin-like protein, SPY1, regulates the ERα and ERK1/2 pathways promoting tamoxifen resistance.
Ferraiuolo RM, Tubman J, Sinha I, Hamm C, Porter LA. Ferraiuolo RM, et al. Oncotarget. 2017 Apr 4;8(14):23337-23352. doi: 10.18632/oncotarget.15578. Oncotarget. 2017. PMID: 28423577 Free PMC article.
References
- Proc Natl Acad Sci U S A. 1974 Apr;71(4):1286-90 - PubMed
- Oncogene. 1996 Feb 15;12(4):753-63 - PubMed
- Cancer Res. 1983 Sep;43(9):4007-10 - PubMed
- Eur J Cancer Clin Oncol. 1983 May;19(5):615-21 - PubMed
- Cancer Res. 1987 Dec 15;47(24 Pt 1):6517-21 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials